ASX - By Stock
|
PAA Biotech |
Re:
2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD
|
|
bunyipt
|
153 |
41K |
10 |
15/12/22 |
15/12/22 |
ASX - By Stock
|
153
|
41K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD
|
|
bunyipt
|
153 |
41K |
10 |
08/12/22 |
08/12/22 |
ASX - By Stock
|
153
|
41K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
2023 , MND, K9 Cancer Commercial Deal , Covid , Human Cancer, OHD
|
|
bunyipt
|
153 |
41K |
11 |
07/12/22 |
07/12/22 |
ASX - By Stock
|
153
|
41K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Top Fifty PAA Share Holders as at 30 November 2022
|
|
bunyipt
|
8 |
2.3K |
9 |
01/12/22 |
01/12/22 |
ASX - By Stock
|
8
|
2.3K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
PAA Post AGM ,, 2022 Highlights
|
|
bunyipt
|
207 |
48K |
18 |
14/11/22 |
14/11/22 |
ASX - By Stock
|
207
|
48K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
2022 Moving Toward 2023
|
|
bunyipt
|
92 |
20K |
5 |
03/11/22 |
03/11/22 |
ASX - By Stock
|
92
|
20K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
AGM Questions 2022
|
|
bunyipt
|
78 |
17K |
13 |
30/10/22 |
30/10/22 |
ASX - By Stock
|
78
|
17K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
AGM Questions 2022
|
|
bunyipt
|
78 |
17K |
12 |
17/10/22 |
17/10/22 |
ASX - By Stock
|
78
|
17K
|
12
|
|
ASX - By Stock
|
WRK Technology |
Re:
Link Group - Clearing House - CDR
|
|
bunyipt
|
167 |
260K |
2 |
26/09/22 |
26/09/22 |
ASX - By Stock
|
167
|
260K
|
2
|
|
ASX - By Stock
|
KDY |
Re:
Ann: Response to ASX Query
|
|
bunyipt
|
56 |
20K |
4 |
11/09/22 |
11/09/22 |
ASX - By Stock
|
56
|
20K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
TOP 442 SHAREHOLDERS AS AT 31 AUGUST 2022WITH VARIATIONS
|
|
bunyipt
|
30 |
7.6K |
2 |
06/09/22 |
06/09/22 |
ASX - By Stock
|
30
|
7.6K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
TOP 442 SHAREHOLDERS AS AT 31 AUGUST 2022WITH VARIATIONS
|
|
bunyipt
|
30 |
7.6K |
3 |
06/09/22 |
06/09/22 |
ASX - By Stock
|
30
|
7.6K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on PharmAust Canine Cancer Trials
|
|
bunyipt
|
216 |
48K |
5 |
30/08/22 |
30/08/22 |
ASX - By Stock
|
216
|
48K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on PharmAust Canine Cancer Trials
|
|
bunyipt
|
216 |
48K |
3 |
28/08/22 |
28/08/22 |
ASX - By Stock
|
216
|
48K
|
3
|
|
ASX - By Stock
|
KDY |
Re:
Ann: DW8 Secures Institutional Funding Launches Entitlement Offer
|
|
bunyipt
|
413 |
119K |
12 |
22/08/22 |
22/08/22 |
ASX - By Stock
|
413
|
119K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Update on PharmAust Canine Cancer Trials
|
|
bunyipt
|
216 |
48K |
13 |
17/08/22 |
17/08/22 |
ASX - By Stock
|
216
|
48K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
bunyipt
|
44 |
10K |
6 |
23/07/22 |
23/07/22 |
ASX - By Stock
|
44
|
10K
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III
|
|
bunyipt
|
1.4K |
377K |
17 |
09/07/22 |
09/07/22 |
ASX - By Stock
|
1.4K
|
377K
|
17
|
|
ASX - By Stock
|
WRK |
Re:
Ann: Extension of Chief Executive Officer Services Contract
|
|
bunyipt
|
17 |
4.9K |
1 |
30/06/22 |
30/06/22 |
ASX - By Stock
|
17
|
4.9K
|
1
|
|
ASX - By Stock
|
WRK |
Re:
Ann: Extension of Chief Executive Officer Services Contract
|
|
bunyipt
|
17 |
4.9K |
1 |
29/06/22 |
29/06/22 |
ASX - By Stock
|
17
|
4.9K
|
1
|
|
ASX - By Stock
|
KDY |
next announcement
|
|
bunyipt
|
0 |
537 |
9 |
15/06/22 |
15/06/22 |
ASX - By Stock
|
0
|
537
|
9
|
|
ASX - By Stock
|
KDY |
Re:
Ann: S&P DJI Announces June 2022 Quarterly Rebalance
|
|
bunyipt
|
34 |
12K |
9 |
05/06/22 |
05/06/22 |
ASX - By Stock
|
34
|
12K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Clinical Trials Interview June 2022
|
|
bunyipt
|
16 |
4.3K |
13 |
04/06/22 |
04/06/22 |
ASX - By Stock
|
16
|
4.3K
|
13
|
|
ASX - By Stock
|
KDY |
Re:
DW8 Growth
|
|
bunyipt
|
16K |
5.1M |
13 |
19/05/22 |
19/05/22 |
ASX - By Stock
|
16K
|
5.1M
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives $210k prepayment of forecast R&D rebate
|
|
bunyipt
|
57 |
10K |
1 |
19/05/22 |
19/05/22 |
ASX - By Stock
|
57
|
10K
|
1
|
|
ASX - By Stock
|
KDY |
Re:
DW8 Growth
|
|
bunyipt
|
16K |
5.1M |
3 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
16K
|
5.1M
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders as at 30 April 2022 - With Variations
|
|
bunyipt
|
34 |
8.8K |
12 |
08/05/22 |
08/05/22 |
ASX - By Stock
|
34
|
8.8K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Top 100 Shareholders as at 31 March 2022 - With Variations
|
|
bunyipt
|
3 |
1.2K |
6 |
01/04/22 |
01/04/22 |
ASX - By Stock
|
3
|
1.2K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Human Trialing Commencement in 60 Days
|
|
bunyipt
|
35 |
7.2K |
8 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
35
|
7.2K
|
8
|
|
ASX - By Stock
|
KDY |
Re:
DW8 Growth
|
|
bunyipt
|
16K |
5.1M |
11 |
12/02/22 |
12/02/22 |
ASX - By Stock
|
16K
|
5.1M
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Epichem CEO
|
|
bunyipt
|
25 |
6.4K |
1 |
06/02/22 |
06/02/22 |
ASX - By Stock
|
25
|
6.4K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Resignation of Epichem CEO
|
|
bunyipt
|
25 |
6.4K |
13 |
03/02/22 |
03/02/22 |
ASX - By Stock
|
25
|
6.4K
|
13
|
|
ASX - By Stock
|
KDY |
Re:
DW8 Growth
|
|
bunyipt
|
16K |
5.1M |
4 |
01/02/22 |
01/02/22 |
ASX - By Stock
|
16K
|
5.1M
|
4
|
|
ASX - By Stock
|
WRK Managed Funds |
Re:
Wrkr Platform uptake
|
|
bunyipt
|
224 |
442K |
1 |
30/01/22 |
30/01/22 |
ASX - By Stock
|
224
|
442K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Shareholder Update - Progress and Strategy
|
|
bunyipt
|
30 |
7.0K |
14 |
13/12/21 |
13/12/21 |
ASX - By Stock
|
30
|
7.0K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL Manufacturing and Human Trials Update
|
|
bunyipt
|
50 |
9.6K |
1 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
50
|
9.6K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL Manufacturing and Human Trials Update
|
|
bunyipt
|
50 |
9.6K |
2 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
50
|
9.6K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL Manufacturing and Human Trials Update
|
|
bunyipt
|
50 |
9.6K |
1 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
50
|
9.6K
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Phase 3 Canines Lymphoma B Trial ( what to expect)
|
|
bunyipt
|
98 |
21K |
10 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
98
|
21K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
The Home Stretch
|
|
bunyipt
|
360 |
82K |
2 |
12/10/21 |
12/10/21 |
ASX - By Stock
|
360
|
82K
|
2
|
|
ASX - By Stock
|
KDY |
Re:
Price targets for 24/12/21 (ONLY)
|
|
bunyipt
|
260 |
118K |
2 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
260
|
118K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Oral Treatment for Covid 19, Human Phase I Trials
|
|
bunyipt
|
132 |
28K |
1 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
132
|
28K
|
1
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Oral Treatment for Covid 19, Human Phase I Trials
|
|
bunyipt
|
132 |
28K |
2 |
09/08/21 |
09/08/21 |
ASX - By Stock
|
132
|
28K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
bunyipt
|
197 |
35K |
2 |
02/08/21 |
02/08/21 |
ASX - By Stock
|
197
|
35K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C and Quarterly Update
|
|
bunyipt
|
197 |
35K |
9 |
30/07/21 |
30/07/21 |
ASX - By Stock
|
197
|
35K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Science Week Conference Presentation
|
|
bunyipt
|
15 |
3.6K |
11 |
09/07/21 |
09/07/21 |
ASX - By Stock
|
15
|
3.6K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Top 50 Shareholders
|
|
bunyipt
|
29 |
6.9K |
6 |
03/06/21 |
03/06/21 |
ASX - By Stock
|
29
|
6.9K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
bunyipt
|
732 |
146K |
6 |
12/05/21 |
12/05/21 |
ASX - By Stock
|
732
|
146K
|
6
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity
|
|
bunyipt
|
732 |
146K |
17 |
06/05/21 |
06/05/21 |
ASX - By Stock
|
732
|
146K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Phase IIb Canine Trial Identifies Therapeutic Window for MPL
|
|
bunyipt
|
98 |
18K |
8 |
30/04/21 |
30/04/21 |
ASX - By Stock
|
98
|
18K
|
8
|
|